Podoplanin-expressing cells derived from bone marrow play a crucial role in postnatal lymphatic neovascularization by �쑄�쁺�꽠
Podoplanin-expressing Cells Derived from Bone Marrow Play a
Crucial Role in Postnatal Lymphatic Neovascularization
Ji Yoon Lee, MS1,4, Changwon Park, PhD1,4,5, Yong Pil Cho, MD, PhD2, Eugine Lee, BS1,
Hyongbum Kim, MD, PhD1, Pilhan Kim, Ph.D3, Seok H. Yun, Ph.D3, and Young-sup Yoon,
MD, PhD1
1Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta,
GA, 30322, USA
2Department of Vascular Surgery, Asan Medical Center, University of Ulsan College of Medicine,
388-1 Pungnap-2dong, Songpa-gu, Seoul 138-736, Korea
3Harvard Medical School and Massachusetts General Hospital, Wellman Center for
Photomedicine, Boston, Massachusetts 02114, USA
Abstract
Background—Emerging evidence has suggested a contribution of bone marrow (BM) cells to
lymphatic vessel formation; however, the exact phenotype of the cells with lymphatic endothelial
progenitor cell (LEPC) function has yet to be identified. Here we investigate the identity of BM-
derived LEPCs and their role in lymphatic neovascularization.
Methods and Results—Culture of BM-mononuclear cells (MNCs) in the presence of VEGFA,
VEGFC and EGF resulted in expression of lymphatic endothelial cell (LEC) markers. Among
these cells, podoplanin+ cells were isolated by magnetic-labeled cell separation system (MACS)
and characterized by FACS and immunocytochemistry. These podoplanin+ cells highly express
markers for LECs, hematopoietic lineages, and stem/progenitor cells, and upon further cultivation,
generate LECs. We further confirmed that podoplanin+ cells exist in small numbers in BM and
peripheral blood (PB) of normal mice, but are significantly (15 fold) augmented upon
lymphangiogenic stimuli such as tumor implantation. Next, to evaluate the potential of
podoplanin+ cells for the formation of new lymphatic vessels in vivo, we injected culture-isolated
or freshly isolated BM-derived podoplanin+ cells into wound and tumor models.
Immunohistochemistry demonstrated that the injected cells were incorporated into the lymphatic
vasculature, displayed LEC phenotypes, and increased lymphatic vascular density in tissues,
suggesting lymphvasculogenesis. Podoplanin+ cells also expressed high levels of
lymphangiogenic cytokines and increased proliferation of LECs during co-culture, suggesting a
lymphangiogenic or paracrine role.
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Conclusions—Our results provide compelling evidence that BM-derived podoplanin+ cells, a
previously unrecognized cell type, function as LEPCs and participate in postnatal lymphatic
neovascularization through both lymphvasculogenesis and lymphangiogenesis.
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INTRODUCTION
Lymphatic vessels play an important role in the pathogenesis of diseases such as
lymphedema and tumors1, 2, and an understanding of lymphatic biology is crucial in order
to develop strategies to prevent or treat these diseases. Investigation of lymphatic vascular
growth was made possible by the discovery of specific markers for lymphatic endothelial
cells (LECs). The establishment of the lymphatic vasculature during mouse embryogenesis
begins with expression of homeobox transcriptional factor PROX-1 in a subset of the venous
endothelial cells of the cardinal vein3 which express VEGFR-34 and LYVE-15.
Subsequently, the PROX-1 expressing (PROX-1+) cells migrate out to form the primary
lymphatic plexus, which undergoes further remodeling to form a mature network of
lymphatic endothelial cells (LECs) which express other lymphatic endothelial cell markers
such as podoplanin6, 7. Podoplanin (pod) is a 38 kDa integral membrane mucoprotein which
is predominantly expressed in the endothelium of lymphatic capillaries7. Mice deficient in
pod die at birth due to respiratory failure accompanied by malfunctioning lymphatic, but not
blood, vessels with impaired lymphatic transport and congenital lymphedema8.
The generation of lymphatic vessels in adults was previously believed to be achieved
exclusively by a process called lymphangiogenesis, the formation of new lymphatic vessels
from preexisting lymphatic vasculature9–13. However, emerging evidence has suggested
that lymphvasculogenesis may also occur through putative progenitor cells for LECs.
Studies have shown that BM contains cells with the potential to generate LECs14–17. An
early study reported that human fetal liver-derived, non-adherent CD34+CD133+VEGFR-3+
cells, when cultured, became adherent and expressed LYVE-1 or pod, implying a role for
these cells as common blood vascular and lymphatic endothelial progenitor cells
(LEPCs)14. Subsequently, Religa and colleagues showed that BM-derived cells were
incorporated into newly formed lymphatic vessels in corneas, using a chimeric mouse model
in which BM of wild-type mice was reconstituted by BM transplantation from donor green
fluorescent protein (GFP) mice16. Maruyama and his colleagues demonstrated incorporation
of mouse GFP-BM cells into lymphatic vessels in inflamed corneas15. This study showed
that tissue resident CD11b+ macrophages, presumably derived from BM, were incorporated
into inflammation-induced lymphatics in the cornea. Kerjaschki et al demonstrated the
presence of male recipient-derived LECs in the lymphatic vessels in kidneys transplanted
from female donors17. Together, these studies support the idea that a certain population of
BM cells, likely of monocyte-macrophage lineages, can give rise to LECs in the foci of new
lymphatic vessel formation (lymphatic neovascularization) in various pathologic conditions.
However, no studies have clearly addressed the exact identity of BM-derived LEPCs in
adults and tested their potential for lymphatic neovascularization by external implantation of
isolated LEPCs.
In this study, we for the first time show that pod+CD11b+ cells exist in adult BM and can
function as LEPCs, and further demonstrate that these cells contribute to lymphatic
neovascularization through dual lymphvasculogenic and lymphangiogenic roles.
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METHODS
All protocols for animal experiments were approved by the Institutional Animal Care and
Use Committees of Emory University.
Culture of BM-MNCs
Mouse BM-MNCs fractionated by density gradient centrifugation with Histopaque®-1083
(Sigma, St. Louis, MO) were seeded onto 100 mm culture dishes coated with rat vitronectin.
To optimize culture conditions to generate LEPCs, four different combinations of media
were employed (online-only Data Supplemental Table 1). To differentiate sorted putative
LEPCs derived from cultured BM-MNCs into LECs, the cells were maintained in EBM-2
supplemented with cytokine cocktail (SingleQuots; Clonetics) for 7 days.
LEC proliferation assay
The sorted pod+ and pod− cells (2.5 × 103) from 4 day-cultured BM-MNCs were mixed with
human dermal lymphatic endothelial cells (hDLECs, 1.5 × 104)(Cambrex) which were pre-
labeled with CM-Dil (Invitrogen), seeded onto 96 well culture plates and cocultured in EGM
media with 1% FBS. Twenty four hours later, cells were stained with Ki67 antibody and
counterstained with DAPI. Cells positive for Dil, Ki67 and DAPI were counted.
Mouse Cornea Model
A micropocket was created followed by implantation of a micropellet containing VEGF-C
and FGF-218. Subsequently, CM-Dil-labeled 4-day cultured pod+ cells were injected into
the surrounding area in the cornea. Eyeballs were isolated 7 days later and subjected to
immunohistochemistry.
Skin and Ear Wound Models
After creating full-thickness excisional skin wounds on backs or ears of the mice, pod+ cells
labeled with DiI or derived from GFP mice were injected into the wound bed around the
wound. Seven days later, the wound tissues including a perimeter of 1 to 2 mm of normal
skin tissue were harvested for immunohistochemistry.
Mouse Tumor (Melanoma) Model
Tumor cells (B16-F1 melanoma cell line) were subcutaneously injected into the middle
dorsum of C57BL/6 mice. Seven days later, Dil-labeled pod+ cells isolated from cultured
BM-MNCs were injected into the tumor vicinity and the mice were sacrificed 7 days later
for immunohistochemistry.
Measurement of lymphatic capillary density
After implantation of tumors (melanomas) and injection of pod+ and pod− cells or the same
volume of PBS as described above, tumors and surrounding peritumoral tissues including
skin were harvested and subjected to immunohistochemistry with a VEGFR-3 antibody19.
Lymphatic capillary density was calculated from at least 10 randomly selected fields.
Statistical Analysis
All results were presented as mean ± SE. Statistical analyses were performed with the
Mann-Whitney U test for comparisons between two groups and the Kruskal-Wallis ANOVA
test for more than two groups. P values < 0.05 were considered to denote statistical
significance.
Details on the above and other methods can be found in the online-only Data Supplement.
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RESULTS
BM-MNCs cultured under defined conditions express LEC markers
To explore whether BM-MNCs include potential LEPCs, we first examined LEC marker
expression in freshly isolated BM-MNCs of FVB mice by qRT-PCR. Uncultured BM-
MNCs expressed Cd31 and Lyve1 but not Prox1, Vegfr3 or pod (Figure 1A). Next, to
investigate whether culture of BM-MNCs under defined conditions can induce LEC gene
expression, we cultured BM-MNCs in EBM-2 supplemented with VEGF-A, VEGF-C, and
EGF individually or in various combinations (online-only Data Supplemental Table 1). We
selected VEGF-A and VEGF-C based on their known role as lymphatic growth factors11,
20 and EGF due to its role in cell proliferation21. Expression of Prox1 and Vegfr3 emerged
at day 1, reached a peak at day 4, and decreased but continued until day 7. Pod expression
went up from day 1 and was sustained until day 10, while Cd31 and Lyve1 expression
decreased over the 4 days (Figure 1A). Another lymphatic marker, Foxc2, was also
expressed in the VEGF-A, VEGF-C and EGF (ACE) condition with a peak at day 4 (data
not shown). From these experiments, we found that cultivation of BM-MNCs with
lymphangiogenic factors can generate LEC-like cells. We further found that 4 day-culture
under the ACE condition was optimal for generating LEC-like cells, as all the LEC markers
were significantly expressed while expression of a pan-vascular endothelial cell marker,
Cd31, was significantly reduced at day 4. Immunocytochemistry and FACS analysis also
confirmed the qRT-PCR results (Figure 1B and 1J). FACS analyses showed a significant
increase in pod+ and VEGFR-3+ cells and similar levels of LYVE-1+ cells in cultured BM-
MNCs compared to the freshly isolated BM-MNCs (Figure 1J). The expression levels of
LEC markers in the pod+ cells were similar to those of mouse LECs isolated from a mouse
EC line, SVEC4-1022 (online-only Data Supplemental Figure S1). Taken together, these
results indicate that culture of BM-MNCs under the ACE condition can generate cells
expressing LEC markers. We therefore used this culture condition for the following
experiments.
Pod+ cells isolated from cultured BM-MNCs express LEC markers, hematopoietic and
stem/progenitor cell markers, and lymphangiogenic cytokines
Since these cultured cells were still heterogeneous, we next sought to enrich cells with the
LEC phenotype using a cell sorting strategy. Among the three representative LEC surface
markers, LYVE-1, VEGFR-3 and pod, we selected pod based on the qRT-PCR data (Figure
1A), which showed pod expression to be the most stable from day 4 and on. Pod has been
implicated in proper patterning of lymphatic vessels and lymphedema7, 8. Accordingly, we
isolated pod+ or pod− cells from the cultured BM-MNCs at day 4 by MACS and examined
the LEC markers. qRT-PCR analysis demonstrated augmented expression of Prox1 (3.7-
fold), Lyve1 (3.0-fold) and pod (6.0-fold) in the pod+ fraction compared to the pod− fraction
(Figure 2A). Vegfr3 expression was slightly higher in the pod+ than the pod− cells.
However, pod+ cells showed lower expression of Cd31 (3.6-fold). qRT-PCR analysis further
revealed that representative lymphangiogenic cytokines such as Vegfa (2.1-fold), Vegfc (3.8-
fold), Vegfd (6.8-fold), Igf1 (8.9-fold), Ang1 (4.8-fold), Hgf (48.1-fold), and bFgf (14.4-
fold), were more highly expressed in pod+ cells than pod− cells, implying more potent
paracrine lymphangiogenic activity of pod+ cells (Figure 2B)2, 23, 24 Next, we examined
the progenitor character of pod+ cells. FACS analysis showed that hematopoietic stem cell
(HSC) markers Sca-1, c-KIT and FLK-1 were expressed in 17.8 ± 3.4%, 13.6 ± 2.4% and
8.6 ± 0.9% of the pod+ cells, respectively (Figure 2C). In contrast, pod− cells virtually did
not express HSC markers. More than 99% of cultured pod+ cells expressed CD45 (Figure
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2D) indicating that these pod+ cells are hematopoietic in origin and are not contaminating
pre-existing LECs from BM. Importantly, when further cultured for 7 days in conventional
LEC culture media, which is EBM-2 supplemented with SingleQuots® (complete EGM)25,
the pod+ cells maintained expression of pod and LYVE-1, whereas pod− cells hardly
expressed these markers (Figure 2E). We also found that the pod+ cells have multi-lineage
differentiation potential, as demonstrated by expression of markers of blood endothelial
cells, smooth muscle cells, and fibroblasts depending upon culture conditions (online-only
Data Supplemental Figure S2). Taken together, these findings indicate that pod+ cells
isolated from cultured BM-MNCs are enriched with LEC markers and lymphangiogenic
cytokines, are hematopoietic in origin, possess stem/progenitor cell characteristics, and
differentiate into LECs when further cultured, suggestive of putative LEPCs.
Culture-isolated pod+ cells contribute to lymphatic vessel formation in animal models
Next, we sought to determine the lymphatic neovascularization potential of these pod+ cells.
We thus injected pod+ cells into four different animal models which are well-known to
induce lymphatic vessel formation, a corneal micropocket model15 (Figure 3A), ear and
skin wound models26 (Figure 3B, 3D and 3E) and a tumor (melanoma) model27 (Figure
3C). Culture-isolated pod+ cells pre-labeled with DiI, a red fluorescent dye used for cell
tracking, were injected into the margin of the cornea (cornea model) or into the
subcutaneous tissues (wound models or tumor model). The tissues were harvested 7 days
later and subjected to immunohistochemistry. Three dimensional (3-D) reconstruction of the
confocal microscopic images demonstrated that pod+ cells were clearly incorporated into
lymphatic vessels and colocalized with cells expressing LEC markers in tissues harvested
from all four models (Figure 3A through C and online-only Data Supplemental Video 1).
The percentage of the LYVE-1+ lymphatic vessels containing Dil+ cells was around 5.2 ±
2.1% in the cornea, 5.5 ± 2.5% in wound models and 8.5 ± 3.7% in the tumor model,
respectively. Of note, the Z-stacked, 3-D images of Figure 3C (tumor model) unequivocally
showed that pod+ cells were incorporated into lymphatic vessels, exhibited a LEC marker,
and had single nuclei, suggesting lymphvasculogenesis from the injected pod+ cells. In
addition, in vivo Video-rate Laser Scanning microscopy demonstrated incorporation and
colocalization of the injected pod+ cells into LYVE-1+ lymphatic vessels at multiple sites in
the ear wound (Figure 3D) and the cornea (data not shown) models. Immunohistochemistry
further confirmed the incorporation of the injected cells into pod-expressing vessels, which
displayed typical lymphatic vessel morphology (online-only Data Supplemental Figure S3).
To complement these results with Dil-labeled pod+ cells, we performed another experiment
in which pod+ cells culture-isolated from GFP mice were injected into a skin wound model
(Figure 3E and online-only Data Supplemental Video 2). Confocal microscopic imaging
revealed that GFP+ cells were incorporated into lymphatic vessels and expressed LYVE-1.
We also found that a larger portion of the injected cells were localized in close proximity to
the lymphatic vasculature in the ear wound, tumor and cornea models (Figure 3D, 4A,
online-only Data Supplemental Figure S4), suggesting their lymphangiogenic role. To
determine the overall lymphatic neovascularization potential of pod+ cells, we measured
lymphatic vascular density in peritumoral tissues and found that pod+ cell-injected tissues
showed significantly higher lymphatic vascular density than PBS- or pod− cell-injected
tissues (Figure 4B and 4C). To further explore their lymphangiogenic role, we cocultured
pod+ cells with DiI-labeled human dermal LECs and determined the proliferation of LECs
by Ki67 staining. The number of Ki67-positive LECs were more than 2 fold higher in the
pod+ cell-cocultured LECs than PBS-added or pod− cell-cocultured LECs (Figure 4D and
4E). In agreement with these data, lymphangiogenic cytokines in tissues measured at day 7
after injection of 2 × 106 pod+ cells in the skin wound model were significantly increased in
the pod+ cell-injected mice, compared to PBS- or pod−-cell injected tissues (Figure 4F).
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From these in vitro and in vivo studies, we concluded that culture-isolated pod+ cells have
dual lymphvasculogenic and lymphangiogenic roles and augment lymphatic
neovascularization.
Pod+ cells are increased in BM and PB under lymphangiogenic conditions, and pod+ cells
contribute to lymphatic neovascularization
Next, we investigated whether pod+ cells directly isolated from animals could function
similarly to culture-driven pod+ cells. As only a small number of BM-MNCs are pod+ in the
steady-state normal animal (Figure 1J), we hypothesized that if these cells function as
LEPCs, the number would be increased in the BM and/or PB under conditions promoting
lymphatic vascular growth. Hence, we injected B16-F1 melanoma cells27 subcutaneously
into the backs of mice, and the number of pod+ cells in BM and PB was examined 7 days
later by FACS. FACS analysis showed that pod+ cells in BM and PB were less than 0.5% in
healthy C57/BL6 mice but increased about 15-fold both in BM and PB upon the growth of
melanoma (BM: 0.2 ± 0.5% vs. 3.2 ± 1.0%, PB: 0.4 ± 0.3% vs. 6.7 ± 2.0%, P < 0.01)
(Figure 5A and 5C). Similar results were found in nude mice implanted with MDA-MB-231
human breast cancer cells (data not shown). Next, we examined the expression of
VEGFR-3, LYVE-1 and c-KIT in pod+ cells isolated from BM and PB of normal and tumor-
bearing mice to determine the progenitor and lymphatic character of the pod+ cells. FACS
analysis of BM cells showed that among the pod+ population, the c-KIT+ or VEGFR-3+, but
not LYVE-1+ cells, were more highly enriched in the tumor (melanoma)-bearing mice than
in the normal mice (Figure 5B). The frequency of c-KIT+ cells in the pod+ population of
tumor bearing mice was 24.8 ± 3.3%, whereas approximately 16.3 ± 2.0% of c-KIT+ cells
were positive for podoplanin (online-only Data Supplemental Figure S5). In PB cells,
among the pod+ population, VEGFR-3+ or LYVE-1+, but not c-KIT+ cells were more
enriched in the tumor-bearing mice than in the normal mice. These findings suggest that
during the process of lymphatic vascular growth, pod+ cells not only increase in number but
also undergo qualitative changes into more lymphatic and progenitor-like cells, as evidenced
by an increase in VEGFR-3, LYVE-1, and c-KIT, respectively. We also observed
differences between BM and PB in the composition of these markers. In BM, c-KIT
expression was higher in tumor mice than normal mice; however in PB, there was no
difference in c-KIT expression between the two (left panels in Figure 5B and 5D). On the
other hand, there was no difference in LYVE-1 expression in BM between tumor mice and
normal mice, but in PB, the expression was higher in tumor mice than normal mice (right
panels in Figure 5B and 5D). In summary, among pod+ cells, c-KIT+ cells were more
enriched in BM and LYVE-1+ cells were more enriched in PB in tumor mice compared to
normal mice. Since stem/progenitor cells are more predominant in BM and undergo
differentiation during mobilization into PB, these results imply that among pod+ cells,
progenitor forms are more prevalent in BM, and during and after mobilization into PB, the
composition of pod+ cells shifts to more lymphatic and less progenitor-like phenotypes. The
increase in absolute percentage of VEGFR-3+ cells among the pod+ population in PB in
comparison to BM further supports this interpretation (middle panels in Figure 5B and 5D).
Finally, to determine the lymphvasculogenic potential of freshly isolated BM pod+ cells in
vivo, we injected the pod+ cells (Dil-labeled) derived from BM of tumor-bearing mice into
skin and ear wound models. Immunohistochemistry showed that the injected cells were
incorporated into lymphatic vessels and exhibited a LEC marker (Figure 6A and 6B).
Together, these results demonstrated that pod+ cells are present in BM and PB, are increased
in number under lymphatic vascular growth conditions, and contribute to
lymphvasculogenesis, suggesting a pathophysiologic role of pod+ cells as LEPCs in vivo.
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Podoplanin is a determining marker to confer lymphatic and progenitor cell properties
Since previous studies documented that tissue resident CD11b+ macrophages express LEC
markers and could contribute to lymphatic vessel formation15, we further explored the
relationship between pod and CD11b in BM-MNCs using FACS analysis. Approximately
50% of the freshly isolated BM-MNCs expressed CD11b, but less than 1% expressed pod
(Figure 7A, left panel). In freshly isolated BM-MNCs, 85% of the pod+ cells expressed
CD11b; however, only 2% of the CD11b+ cells expressed pod, showing that the majority of
pod+ cells express CD11b but most CD11b+ cells are negative for pod. When cultured in the
ACE condition for 4 days, 22% of total cells expressed pod and 62% expressed CD11b,
(Figure 7A, right panel) indicating an increase in both pod+ cells and CD11b+ cells, but
greater enrichment of pod+, cells during lymphatic activation. More than 99% of these pod+
cells expressed CD11b but only 33% of CD11b+ cells expressed pod, indicating that when
activated by lymphangiogenic cytokines, pod+ cells can virtually represent pod+CD11b+
cells; however, two-thirds of CD11b+ cells are negative for pod (Figure 7A, right panel).
This argument is supported by the in vivo finding that the frequency of pod+CD11b+ cells
was increased in BM of tumor bearing mice undergoing active lymphatic neovascularization
(online-only Data Supplemental Figure S6). Together, these results suggest that during
lymphatic activation, the frequency of BM cells expressing either pod or CD11b is
increased, but especially so for cells expressing both pod and CD11b.
Next, to further define the phenotype of podoplanin- or CD11b-expressing cells, we
investigated expression of other LEC markers (VEGFR-3, LYVE1) and stem/progenitor
markers (c-KIT and Sca-1) in each cell fraction (Figure 7B). FACS analysis showed that
VEGFR-3+ cells and LYVE-1+ cells were present almost exclusively in the pod+ population,
of which the majority was pod+CD11b+ (fraction II in Figure 7A). These results suggest that
the pod+ cell population includes almost all the cells having LEC phenotypes.
Approximately 99% of c-KIT+ cells and 90% of Sca-1+ cells were also restricted to the
pod+CD11b+ cell fraction (Figure 7B), i.e., pod+ cell fraction, and only a negligible number
of those cells were present in the pod−CD11b+ cell fraction (Figure 7A, fraction II vs. I).
Morphology of the two cell populations was distinctively different. The pod+CD11b+ cells
were attached and grew as a monolayer, whereas the pod−CD11b+ cells were floating and
maintained a round cell morphology (online-only Data Supplemental Figure S7).
Importantly, when the isolated pod+CD11b+ or pod−CD11b+ cells were further cultured for
7 days in complete EGM, the pod+CD11b+ cells robustly expressed pod, LYVE-1,
VEGFR-3 and PROX-1, while the pod−CD11b+ cells minimally expressed pod and did not
express LYVE-1, VEGFR-3 or PROX-1 (Figure 7C through 7X). These data indicate that
almost all the stem/progenitor cells were exclusively restricted to the pod+CD11b+, i.e.,
pod+ cell population. As a whole, these findings suggest that pod, more than CD11b, is a
determining marker to confer lymphatic as well as progenitor cell properties upon BM cells,
robustly supporting the role of pod+ cells as LEPCs.
Loss of hematopoietic properties of pod+CD11b+ cells during differentiation into LECs
We next investigated whether the hematopoietic character of the putative LEPCs or
pod+CD11b+ cells is lost during differentiation into LECs. Pod+CD11b+ or pod−CD11b+
cells isolated from cultured BM-MNCs were further cultured for 7 days in complete EGM.
Immunocytochemistry showed that 7-day cultured pod+CD11b+ cells do not express CD45
while expressing LEC markers including PROX-1 (Figure 7 and Figure 8A–D). In contrast,
7-day cultured pod−CD11b+ cells still maintained CD45 expression with concomitant loss
of LEC markers (Figure 7 and Figure 8E–H). FACS analysis additionally confirmed loss of
CD45 in the further cultured pod+CD11b− cells. Approximately 94% of the pod−CD11b+
cells were CD45 positive (Figure 8I). To further verify these findings in vivo, we injected
DiI-labeled pod+CD11b+ cells sorted from the cultured BM-MNCs into skin wounded mice.
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Figure 8J clearly shows that expression of CD45 was not detected in the pod+CD11b+ cells
incorporated into lymphatic vessels (Figure 8J). These data indicate that pod+CD11b+ cells
lost hematopoietic properties during differentiation into LECs.
DISCCUSION
This is the first study to demonstrate the presence of pod+ cells in the circulatory system and
to provide evidence that these cells can function as LEPCs. Pod+ cells exist in BM and PB in
very low amounts at steady state and increase in number under conditions which promote
lymphatic vascular growth such as melanoma27. Pod+ cells are expandable by culture with
lymphangiogenic growth factors. As lymphangiogenic tumors, such as melanoma or breast
cancer28, or inflammation15, 29 induce an increase in the local concentration of lymphatic
growth factors, the cell culture conditions closely mimic the local environment of these
conditions. We also successfully generated LECs in vitro by further cultivation of these
culture-isolated pod+ cells. Thus this in vitro and in vivo evidence strongly suggests a
crucial role for pod+ cells in lymphatic vessel formation. High expression of other LEC
genes and lymphangiogenic cytokines in pod+ cells further supports their role in lymphatic
neovascularization. The almost exclusive restriction of c-KIT, Sca-1 and FLK-1 expression
to pod+ cells suggests their stem/progenitor cell character.
More direct evidence of lymphatic neovascularization by pod+ cells was provided by the cell
injection studies. Both freshly isolated and cultured pod+ cells were not only incorporated as
LECs into lymphatic vasculature (lymphvasculogenesis) but also highly localized near the
lymphatic vasculature, suggestive of a paracrine or lymphangiogenic role. Although there is
controversy regarding the transdifferentiation potential of BM-derived hematopoietic
cells30, 31, our data support transdifferentiation as a viable mechanism for
lymphvasculogenesis from BM cells. In fact, the prevalent view that terminally
differentiated cells do not change their phenotype has been challenged15–17, 32, 33. B
lymphocytes can become macrophage-like cells upon overexpression of C/EBP transcription
factor34. Fully differentiated somatic cells can be reprogrammed into pluripotent stem cells
with ectopic expression of pluripotency-related transcription factors35. A battery of three
transcription factors was able to convert differentiated exocrine cells into functional β-cells
in adult mice36. Conditional inactivation of Prox1 in adult mice induced cell fate change
from lymphatic endothelial cells into blood endothelial cells25, suggesting plasticity of
differentiated cells. Our data also showed that BM-derived pod+ cells clearly express
PROX-1 and could become LECs in pathological conditions. To determine the contribution
of injected pod+ cells to LECs, we used comprehensive and multimodal approaches. Both
freshly isolated- and culture-isolated pod+ cells were used as cell sources. For cell tracking
in vivo, both DiI-labeled-and GFP-mice derived cells were used. As in vivo models, we used
various animal models such as tumor, inflammation and wound models, which represent the
most prevalent clinical conditions associated with lymphatic vascular growth. The fact that
pod+ cells gave rise to LECs in all these models supports the identity of pod+ cells as
LEPCs. To prove this transdifferentiation, we used both static and in vivo confocal
microscopy technologies and adopted rigorous criteria as follows. As criteria for
transdifferentiation, we required not only the incorporation of injected cells into lymphatic
vessels but also exact colocalization of injected cells showing single nuclei with LEC
marker staining at two different orthogonal images and at multiple z-stacked files. To further
confirm this colocalization, three dimensional reconstructions were used. In addition, for
identification of lymphatic vessels which harbor the injected cells, both positive staining for
multiple lymphatic markers and clear morphology of the vessels were required. These
multiple criteria and high standards insured that we were seeing true transdifferentiation of
injected cells rather than artifacts. Common expression of LYVE-1 in LECs and a
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subpopulation of monocyte-macrophage lineage increases this likelihood of
transdifferentiation as well15, 37, 38.
Our data indicate that pod+ cells also contribute to lymphatic neovascularization through
paracrine lymphangiogenic effects on existing lymphatic vessels. Similar evidence of the
role for BM-derived cells in postnatal lymphangiogenesis in pathologic conditions has been
reported. He et al showed that BM-derived GFP+ cells were heavily recruited to the
periphery of new lymphatic vessels following tumor implantation, although few were
incorporated into lymphatic vessels9. In other reports, depletion of macrophages inhibited
inflammation-induced new lymphatic vessel formation29, 39. Macrophages isolated from
mice undergoing extensive lymphangiogenesis displayed a marked increase in
lymphangiogenic cytokines39, 40. These studies support a specific population of BM-
derived cells playing an important role in lymphangiogenesis.
In this study, we demonstrated that BM cells which express pod as well as CD11b can
function as LEPCs. A recent report showed that CD11b+ macrophages may play an
important role in inflammation-induced lymphvasculogenesis in the cornea15. However, this
study demonstrated only that tissue resident CD11b+ macrophages, which are presumably
derived from BM, show a LEC phenotype. In contrast, our study clearly demonstrated that
BM hematopoietic cells are the source of lymphvasculogenic CD11b+ cells and further
identified, using in vitro culture methods and in vivo physiologic and pathologic conditions,
a specific cell population among the heterogeneous CD11b+, i.e. pod+CD11b+ cells, which
can function as LEPCs.
Our study identifies pod+ cells as LEPCs and proposes their crucial role in
lymphvasculogenesis and lymphangiogenesis. The identification of this phenotype has
important clinical significance. Since a culture isolation protocol has been established, these
cells can be utilized for treating diseases which can benefit from a lymphatic vascular
supply, such as lymphedema or wound healing. Furthermore, the quantification of these
cells in BM may be used to measure or predict tumor burden, progression or metastasis,
allowing their use as a biomarker.
Clinical Summary
In this study, we identified podoplanin-expressing lymphatic endothelial progenitor cells
(LEPC) derived from bone marrow. Injection of these podoplanin-expressing LEPCs into
various animal models showed contribution of the LEPCs to the formation of new
lymphatic vessels through direct transdifferentiation as well as paracrine effects. This
lymphatic vessel forming capability can be utilized for the treatment of lymphedema or
chronic unhealed wounds, which are characterized by lymphatic vascular insufficiency.
Moreover, this study demonstrated an increase in the number of circulating LEPCs in
tumor-bearing mice, suggesting that LEPCs are correlated with tumor-associated
lymphatic vascular growth. This property can be harnessed for development of a
biomarker for monitoring tumor burden, tumor growth and/or metastasis.
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Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We would like to thank Debby Martinson for confocal imaging; Mackenzie Houge and Min-Young Lee for
technical assistance; Andrea Wecker for critical reading of the manuscript; Dr. Mejeong Lee for support for the
initial steps of this project.
Lee et al. Page 9
Circulation. Author manuscript; available in PMC 2011 October 5.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Funding
This work was supported in part by an Idea Grant Award from Department of Defense (W81XWH-09-1-0278),
NIH grants (RO1HL084471, R21HL097353), PHS Grant (UL1 RR025008) from the Clinical and Translational
Science Award program, NIH, NCRR, and a grant (SC4300) from the Stem Cell Research Center of the 21st
Century Frontier Research Program funded by the Ministry of Science and Technology, Republic of Korea.
REFERENCES
1. Achen MG, McColl BK, Stacker SA. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell.
2005; 7:121–127. [PubMed: 15710325]
2. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature.
2005; 438:946–953. [PubMed: 16355212]
3. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system.
Cell. 1999; 98:769–778. [PubMed: 10499794]
4. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M,
Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic
endothelium during development. Proc Natl Acad Sci U S A. 1995; 92:3566–3570. [PubMed:
7724599]
5. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG. LYVE-1, a new
homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol.
1999; 144:789–801. [PubMed: 10037799]
6. Wetterwald A, Hoffstetter W, Cecchini MG, Lanske B, Wagner C, Fleisch H, Atkinson M.
Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and
osteocytes. Bone. 1996; 18:125–132. [PubMed: 8833206]
7. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K,
Weninger W, Tschachler E, Alitalo K, Kerjaschki D. Angiosarcomas express mixed endothelial
phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic
endothelium. Am J Pathol. 1999; 154:385–394. [PubMed: 10027397]
8. Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N, Williams M, Dvorak AM,
Dvorak HF, Oliver G, Detmar M. T1alpha/podoplanin deficiency disrupts normal lymphatic
vasculature formation and causes lymphedema. EMBO J. 2003; 22:3546–3556. [PubMed:
12853470]
9. He Y, Rajantie I, Ilmonen M, Makinen T, Karkkainen MJ, Haiko P, Salven P, Alitalo K. Preexisting
lymphatic endothelium but not endothelial progenitor cells are essential for tumor
lymphangiogenesis and lymphatic metastasis. Cancer Res. 2004; 64:3737–3740. [PubMed:
15172976]
10. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K. Vascular
endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.
Cancer Res. 2001; 61:1786–1790. [PubMed: 11280723]
11. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG,
Talikka M, Rauvala H, Betsholtz C, Alitalo K. Vascular endothelial growth factor C is required for
sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2004; 5:74–80.
[PubMed: 14634646]
12. Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X,
Manseau EJ, Dvorak AM, Dvorak HF. Vascular permeability factor/vascular endothelial growth
factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002; 196:1497–1506.
[PubMed: 12461084]
13. Cao R, Bjorndahl MA, Gallego MI, Chen S, Religa P, Hansen AJ, Cao Y. Hepatocyte growth
factor is a lymphangiogenic factor with an indirect mechanism of action. Blood. 2006; 107:3531–
3536. [PubMed: 16424394]
14. Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S. VEGFR-3 and CD133 identify a population of
CD34+ lymphatic/vascular endothelial precursor cells. Blood. 2003; 101:168–172. [PubMed:
12393704]
Lee et al. Page 10
Circulation. Author manuscript; available in PMC 2011 October 5.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
15. Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, Tomita M, Van Rooijen N, Takenaka H,
D'Amore PA, Stein-Streilein J, Losordo DW, Streilein JW. Inflammation-induced
lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest. 2005;
115:2363–2372. [PubMed: 16138190]
16. Religa P, Cao R, Bjorndahl M, Zhou Z, Zhu Z, Cao Y. Presence of bone marrow-derived
circulating progenitor endothelial cells in the newly formed lymphatic vessels. Blood. 2005;
106:4184–4190. [PubMed: 16141354]
17. Kerjaschki D, Huttary N, Raab I, Regele H, Bojarski-Nagy K, Bartel G, Krober SM, Greinix H,
Rosenmaier A, Karlhofer F, Wick N, Mazal PR. Lymphatic endothelial progenitor cells contribute
to de novo lymphangiogenesis in human renal transplants. Nat Med. 2006; 12:230–234. [PubMed:
16415878]
18. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in
the mouse cornea. Invest Ophthalmol Vis Sci. 1996; 37:1625–1632. [PubMed: 8675406]
19. Yoon YS, Murayama T, Gravereaux E, Tkebuchava T, Silver M, Curry C, Wecker A, Kirchmair
R, Hu CS, Kearney M, Ashare A, Jackson DG, Kubo H, Isner JM, Losordo DW. VEGF-C gene
therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin
Invest. 2003; 111:717–725. [PubMed: 12618526]
20. Hong YK, Lange-Asschenfeldt B, Velasco P, Hirakawa S, Kunstfeld R, Brown LF, Bohlen P,
Senger DR, Detmar M. VEGF-A promotes tissue repair-associated lymphatic vessel formation via
VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J. 2004; 18:1111–1113.
[PubMed: 15132990]
21. Deasy BM, Qu-Peterson Z, Greenberger JS, Huard J. Mechanisms of muscle stem cell expansion
with cytokines. Stem Cells. 2002; 20:50–60. [PubMed: 11796922]
22. Ledgerwood LG, Lal G, Zhang N, Garin A, Esses SJ, Ginhoux F, Merad M, Peche H, Lira SA,
Ding Y, Yang Y, He X, Schuchman EH, Allende ML, Ochando JC, Bromberg JS. The sphingosine
1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T
lymphocytes into afferent lymphatics. Nat Immunol. 2008; 9:42–53. [PubMed: 18037890]
23. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey
K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer
metastasis. Nat Med. 2001; 7:192–198. [PubMed: 11175850]
24. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa
S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics.
Nat Med. 2001; 7:186–191. [PubMed: 11175849]
25. Johnson NC, Dillard ME, Baluk P, McDonald DM, Harvey NL, Frase SL, Oliver G. Lymphatic
endothelial cell identity is reversible and its maintenance requires Prox1 activity. Genes Dev.
2008; 22:3282–3291. [PubMed: 19056883]
26. Maruyama K, Asai J, Ii M, Thorne T, Losordo DW, D'Amore PA. Decreased macrophage number
and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic
wound healing. Am J Pathol. 2007; 170:1178–1191. [PubMed: 17392158]
27. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D,
Wain J, Mark EJ, Munn LL, Jain RK. Lymphatic metastasis in the absence of functional
intratumor lymphatics. Science. 2002; 296:1883–1886. [PubMed: 11976409]
28. Olmeda D, Moreno-Bueno G, Flores JM, Fabra A, Portillo F, Cano A. SNAI1 is required for tumor
growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Res.
2007; 67:11721–11731. [PubMed: 18089802]
29. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D'Amore PA, Dana MR,
Wiegand SJ, Streilein JW. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in
inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004; 113:1040–
1050. [PubMed: 15057311]
30. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental
plasticity of adult hematopoietic stem cells. Science. 2002; 297:2256–2259. [PubMed: 12215650]
31. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB,
Virag JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, Field LJ.
Lee et al. Page 11
Circulation. Author manuscript; available in PMC 2011 October 5.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts.
Nature. 2004; 428:664–668. [PubMed: 15034593]
32. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells
control the angiogenic switch in mouse lung metastasis. Science. 2008; 319:195–198. [PubMed:
18187653]
33. Purhonen S, Palm J, Rossi D, Kaskenpaa N, Rajantie I, Yla-Herttuala S, Alitalo K, Weissman IL,
Salven P. Bone marrow-derived circulating endothelial precursors do not contribute to vascular
endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A. 2008; 105:6620–
6625. [PubMed: 18443294]
34. Xie H, Ye M, Feng R, Graf T. Stepwise reprogramming of B cells into macrophages. Cell. 2004;
117:663–676. [PubMed: 15163413]
35. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of
pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131:861–872.
[PubMed: 18035408]
36. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult pancreatic
exocrine cells to beta-cells. Nature. 2008; 455:627–632. [PubMed: 18754011]
37. Schledzewski K, Falkowski M, Moldenhauer G, Metharom P, Kzhyshkowska J, Ganss R, Demory
A, Falkowska-Hansen B, Kurzen H, Ugurel S, Geginat G, Arnold B, Goerdt S. Lymphatic
endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+
macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures
in vitro: implications for the assessment of lymphangiogenesis. J Pathol. 2006; 209:67–77.
[PubMed: 16482496]
38. Cho HJ, Lee N, Lee JY, Choi YJ, Ii M, Wecker A, Jeong JO, Curry C, Qin G, Yoon YS. Role of
host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the
ischemic heart. J Exp Med. 2007; 204:3257–3269. [PubMed: 18070934]
39. Kataru RP, Jung K, Jang C, Yang H, Schwendener RA, Baik JE, Han SH, Alitalo K, Koh GY.
Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen
clearance, and inflammation resolution. Blood. 2009; 113:5650–5659. [PubMed: 19346498]
40. Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, Cha HJ, Schwendener RA, Jang KY, Kim KS,
Alitalo K, Koh GY. Profound but dysfunctional lymphangiogenesis via vascular endothelial
growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res. 2008;
68:1100–1109. [PubMed: 18281485]
Lee et al. Page 12
Circulation. Author manuscript; available in PMC 2011 October 5.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Expression of LEC markers in BM-MNCs cultured with lymphangiogenic cytokines
A, BM-MNCs were cultured under various culture conditions, harvested at day 1, 4, 7, or
10, and subjected to qRT-PCR. Each value is the average of three independent experiments
(n = 4 per experiment). BM-MNC, bone marrow mononuclear cells; EBM-2, endothelial cell
basal medium-2; A, VEGF-A; C, VEGF-C; E, EGF. B through J, Expression of LEC
markers in 4-day cultured BM-MNCs which were cultured under the ACE condition.
Immunocytochemistry (B–I): DAPI (blue) for nuclear staining, merged image (I) of images
in F–H, scale bar = 100 µm. FACS analysis (J): the numbers in boxes are the percentage of
cells positive for the indicated proteins. Each value is the average of three independent
experiments (n = 4 per experiment).
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Figure 2. Enriched expression of lymphangiogenic cytokines and markers for LECs and HSCs in
the culture-isolated pod+ cells
A through D, The MACS-sorted pod+ and pod− cells from 4 day-cultured BM-MNCs were
subjected to qRT-PCR (A, B) and FACS analysis (C, D). Each value is the average of three
independent experiments (** P<0.01, * P<0.05, n=4 per experiment). E, The sorted cells
were further cultured for 7 days and subjected to immunocytochemistry for LYVE-1 and
pod.
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Figure 3. Lymphvasculogenesis from pod+ cells in animal models
A through C, Mice which had received surgery for cornea micropocket, wound or
implantation of tumor cells (B16-F1 Melanoma) were injected with Dil-labeled pod+ cells
(red) and the tissues were harvested 7 days later for immunohistochemistry. A through C,
Representative confocal images from cornea (A), wounded skin (B) and peritumoral
subcutaneous tissues (C) demonstrated that DiI-labeled pod+ cells were incorporated into
lymphatic vessels and exhibited a LEC marker, LYVE-1. D, In vivo live confocal
microscopic image from an ear wound model showed that multiple pod+ cells (DiI) were
clearly incorporated into lymphatic vessels and colocalized with LYVE-1. Arrows indicate
cells positive for Dil and LYVE-1. Scale bar = 20 µm. E, Skin wound tissues injected with
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pod+ cells from GFP mice were stained for LYVE-1 and examined by confocal microscopy.
Injected pod+ GFP cells (arrows) were incorporated into the lymphatic vessels and
expressed LYVE-1. Representative images from at least two independent experiments for
each animal model are shown (n = 3 per experiment). Scale bar = 10 µm. Blue fluorescence:
DAPI
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Figure 4. Lymphangiogenic characteristics of pod+ cells
A, Pod+ cells sorted from 4-day cultured BM-MNCs labeled with Dil were injected into the
periphery of tumors in mice that had been injected with melanoma cells 7 days before.
Seven days after cell implantation, tumor and peritumoral tissues including skin were
harvested and underwent immunostaining for LYVE-1 (green). The arrows indicate
engraftment of pod+ cells in close proximity to lymphatic vessels. Representative images
from more than two independent experiments are shown (n = 3 per experiment). DAPI
(blue). Scale bar = 20 µm. B, The peritumoral tissues which were injected with pod+ cells,
pod− cells or the same volume of PBS similarly to the procedure described above were
harvested 7 days later and subjected to immunohistochemistry using a VEGFR-3 antibody.
Representative images from at least two independent experiments are shown (n = 2 per
group). Magnification, × 4. C, The number of VEGFR-3+ vessels in peritumoral tissues was
higher in mice implanted with pod+ cells than pod− cells or PBS. The indicated values were
calculated from two independent experiments (B) using more than 10 randomly selected
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fields (** P<0.01, * P<0.05). D, The pod+- and pod− cells from 4 day-cultured BM-MNCs
or PBS were mixed with Dil-labeled hDLECs (red), cultured for 24 hrs and stained for Ki67
(green). DAPI (blue). The cells positive for Dil, Ki67 and DAPI (white arrowheads) were
counted. Representative images from three independent experiments are shown. Scale bar =
20 µm. E, hDLECs cocultured with pod+ cells exhibited a higher rate of Ki67+ cells
compared to controls, suggesting a lymphangiogenic role of pod+ cells on surrounding
LECs. The indicated values are the averages calculated from 14 randomly selected fields of
each group of three independent experiments. (** P<0.01, * P<0.05). F, Tissues from mice
injected with pod+ or pod− cells were subjected to qRT-PCR analyses. Graphs from three
independent experiments are shown (* P<0.05, n=3 per group).
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Figure 5. Augmentation of pod+ cells in BM and PB upon tumor induction
Cells prepared from BM (A, B) or PB (C, D) of normal or tumor (B16-F1 melanoma cells)-
bearing mice were subjected to FACS analysis. Representative images from three
independent experiments are shown (** P<0.01, * P<0.05, n=3 per group).
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Figure 6. Incorporation of freshly isolated pod+ cells into lymphatic vessels
Pod+ cells isolated from BM of tumor-bearing mice were labeled with Dil and injected into
mice in the skin wound (A) or the ear wound model (B). Confocal imaging showed
colocalization of the injected pod+ cells (red) with LYVE-1+ (green) lymphatic vessels in
mice. Representative images from at least two independent experiments for each animal
model are shown (n = 3 per experiment). Scale bar = 20 µm.
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Figure 7. The relationship between podoplanin, CD11b, stem cell markers and LEC markers
A, The uncultured or 4-day cultured BM-MNCs were subjected to FACS analysis for pod
and CD11b. The numbers in each box represent percentage of positive cells. B, The Y axis
represents the relative percentage cells expressing VEGFR-3, LYVE-1, c-KIT or Sca-1 in
the indicated cell fraction of (A). The indicated values are the averages of three independent
experiments (n=4 per experiment). C through X, The culture-isolated pod+CD11b+ or
pod−CD11b+ cells from BM-MNCs were cultured for another 7 days under complete EGM
media and stained for lymphatic markers. Representative images from at least three
independent experiments are shown (n=4 per experiment). Magnification, × 10.
Lee et al. Page 24
Circulation. Author manuscript; available in PMC 2011 October 5.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 8. The pod+CD11b+ cells, but not pod−CD11b+ cells, lose expression of CD45
The culture-isolated pod+CD11b+ or pod−CD11b+ cells from BM-MNCs were further
cultured for 7 days under complete EGM medium and subjected to immuocytochemistry
(A–H) and FACS analysis for CD45 (I). For in vivo injection experiments (J), DiI-labeled
pod+CD11b+ cells from the cultured BM-MNCs were injected into skin wounded mice and
subjected to immunohistochemistry (n = 3 per experiment). The injected DiI-labeled cells
did not express CD45 in tissues.
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